Top Market Shifts Transforming the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Landscape: Key Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Through 2025?
In the past few years, the market for benign prostatic hyperplasia (BPH) treatment devices and equipment has seen significant growth. Projected to expand from $1.27 billion in 2024 to $1.34 billion in 2025, it showcases a compound annual growth rate (CAGR) of 5.9%. The historic growth can be traced back to factors like an aging demographic, increased awareness and diagnosis, better access to healthcare, and the rise in personalized treatment.

What's the Projected Size of the Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market by 2029?
The market for treatment devices and equipment for benign prostatic hyperplasia (BPH) is anticipated to witness significant growth in the coming years, expanding to a value of $1.74 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%. This predicted growth during the forecast period is due to factors including minimally invasive procedures, the expansion of emerging markets, supportive regulatory environment, and value-based healthcare. Key trends projected during the forecast period are non-surgical and office-based treatments, the utilization of laser and radiofrequency technologies, the rise of telemedicine and remote consultations, along with increased patient education and engagement.

View the full report here:
https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-bph-treatment-devices-and-equipment-global-market-report

Top Growth Drivers in the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Industry: What's Accelerating the Market?
The growth of the benign prostatic hyperplasia market is expected to be fueled by the rising number of prostate cancer cases. Prostate cancer is a form of cancer that originates in the prostate gland, a small gland in men situated beneath the bladder, similar in size to a walnut. The surge in prostate cancer incidences frequently results in an increased number of elderly men seeking treatment for prostate-related problems. This in turn leads to the detection and management of benign prostatic hyperplasia. For example, the American Society of Clinical Oncology (ASCO), a US-based professional group that posts patient cancer information on their cancer.net website, estimated that in February 2023, there were about 288,300 men diagnosed with prostate cancer in the United States in that year, with 268,490 new cases and 34,500 deaths caused by prostate cancer in 2022. As such, the rising number of prostate cancer cases is propelling the benign prostatic hyperplasia market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2431&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?
Leading firms in the benign prostatic hyperplasia market, such as Teleflex Incorporated, are concentrating their efforts on producing innovative products like the UroLift 2 System and the UroLift ATC advanced tissue control system, to ensure they offer dependable services. These systems have been designed specifically for addressing lower urinary tract symptoms resulting from benign prostatic hyperplasia (BPH) and were launched in May 2022. With the UroLift 2 System, permanent UroLift implants are delivered through the prostatic urethra lobes, whilst the UroLift ATC system offers a minimally invasive solution for treating symptoms of an enlarged prostate, by lifting and holding the swollen prostate tissue so it no longer obstructs the urethra. This signifies a progressive advancement in the treatment of benign prostatic hyperplasia (BPH).

What Are the Main Segments in the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?
The benign prostatic hyperplasia (bph) treatment devices and equipment market covered in this report is segmented -

1) By Product: Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants
2) By Procedure Type: Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery, Other Procedure Types
3) By End-User: Hospitals, Ambulatory Surgical Centres (ASC), Clinics, Home

Subsegments:
1) By Resectoscopes: Bipolar Resectoscopes, Monopolar Resectoscopes, High-Performance Resectoscopes
2) By Radiofrequency Ablation Device: Single-Needle Radiofrequency Ablation, Multi-Needle Radiofrequency Ablation
3) By Urology Lasers: Holmium Lasers, Diode Lasers, Green Light Lasers
4) By Prostatic Stents: Temporary Prostatic Stents, Permanent Prostatic Stents
5) By Implants: Prostatic Urethral Lift (PUL) Implants, Balloon-Expandable Stents, Permanent Implants for BPH Treatment

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2431&type=smp

Which Top Companies are Driving Growth in the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?
Major companies operating in the benign prostatic hyperplasia (BPH) treatment devices and equipment market include Karl Storz, Lumenis Ltd., Olympus Corporation, Urologix LLC, Boston scientific Inc., Endo International plc, NeoTract Inc., OmniGuide Inc., Medifocus Inc., ProArc Medical Ltd., Teleflex Incorporated, Medtronic plc, Urotech Devices, Prostalund Operations AB, Baxter International, NxThera Inc., Richard Wolf GmbH, Coloplast A/S, Siemens Healthineers, Quest Pharmatech, Protox Therapeutics, IntelGenx Technologies Corp, Astellas Pharma Inc., Ipsen S.A., Biolitec AG, BVM Medical, Convergent Laser Technologies, Cook Medical, GreenLight Technologies, Merit Medical Systems, Pnn Medical A/S, PROCEPT BioRobotics, Prosenex, ProSolv CardioVascular Inc., Quanta System, Rocamed SAM, RZ Medizintechnik GmbH, SRS Medical Systems, UroShape LLC, Vertebron Inc.

Which Regions Will Dominate the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Through 2029?
North America was the largest region in the benign prostatic hyperplasia (BPH) treatment devices and equipment market in 2024. Western Europe was the second-largest region in the global benign prostatic hyperplasia (BPH) treatment devices and equipment market. The regions covered in the benign prostatic hyperplasia (BNH) treatment devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2431

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.